AR105596A1 - PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCIÓN DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICIÓN QUE COMPRENDE IgM, COMPOSICIÓN - Google Patents
PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCIÓN DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICIÓN QUE COMPRENDE IgM, COMPOSICIÓNInfo
- Publication number
- AR105596A1 AR105596A1 ARP160102382A ARP160102382A AR105596A1 AR 105596 A1 AR105596 A1 AR 105596A1 AR P160102382 A ARP160102382 A AR P160102382A AR P160102382 A ARP160102382 A AR P160102382A AR 105596 A1 AR105596 A1 AR 105596A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- igm
- treatment
- infections
- use according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 12
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 206010040047 Sepsis Diseases 0.000 abstract 2
- 230000000845 anti-microbial effect Effects 0.000 abstract 2
- 241000193163 Clostridioides difficile Species 0.000 abstract 1
- 241000193155 Clostridium botulinum Species 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000588747 Klebsiella pneumoniae Species 0.000 abstract 1
- 102000010445 Lactoferrin Human genes 0.000 abstract 1
- 108010063045 Lactoferrin Proteins 0.000 abstract 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract 1
- 241000191967 Staphylococcus aureus Species 0.000 abstract 1
- 241000193998 Streptococcus pneumoniae Species 0.000 abstract 1
- 108010059993 Vancomycin Proteins 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 abstract 1
- 229940078795 lactoferrin Drugs 0.000 abstract 1
- 235000021242 lactoferrin Nutrition 0.000 abstract 1
- 229960002260 meropenem Drugs 0.000 abstract 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
- 229960003165 vancomycin Drugs 0.000 abstract 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 abstract 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Métodos para el tratamiento o la prevención de afecciones inmunitarias relacionadas con infecciones utilizando composiciones que comprenden IgM. Reivindicación 1: Método para el tratamiento de complicaciones inmunitarias producidas por infecciones en pacientes en necesidad del mismo, caracterizado porque comprende la administración de una composición que comprende IgM. Reivindicación 27: Composición que comprende IgM para su uso en el tratamiento de sepsis. Reivindicación 28: Composición para su uso, según la reivindicación 27, caracterizada porque la sepsis es producida por Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Clostridium difficile, Clostridium botulinum, o combinaciones de los mismos. Reivindicación 35: Composición para su uso, según la reivindicación 27, caracterizada porque la IgM es recombinante, derivada de plasma, derivada de cultivo celular, transgénica o sintetizada químicamente. Reivindicación 38: Composición para su uso, según la reivindicación 27, caracterizada porque la composición que comprende IgM se administra junto con una o mas otras composiciones o moléculas seleccionadas entre moléculas antiinflamatorias, antibióticos de molécula pequeña, moléculas que son de naturaleza antimicrobiana, antimicrobianos peptídicos naturales o sintéticos, proteínas con propiedades antimicrobianas, otros inmunomoduladores o combinaciones de los mismos. Reivindicación 39: Composición para su uso, según la reivindicación 38, caracterizada porque dichas otras composiciones o moléculas son vancomicina, meropenem, lactoferrina o combinaciones de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201917P | 2015-08-06 | 2015-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105596A1 true AR105596A1 (es) | 2017-10-18 |
Family
ID=56464076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102382A AR105596A1 (es) | 2015-08-06 | 2016-08-04 | PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCIÓN DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICIÓN QUE COMPRENDE IgM, COMPOSICIÓN |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9913903B2 (es) |
| EP (2) | EP3150629A3 (es) |
| JP (1) | JP6901245B2 (es) |
| KR (1) | KR102739710B1 (es) |
| CN (1) | CN106421780A (es) |
| AR (1) | AR105596A1 (es) |
| AU (1) | AU2016208291B2 (es) |
| CA (1) | CA2936745A1 (es) |
| CL (1) | CL2016001977A1 (es) |
| IL (1) | IL246918B (es) |
| MX (1) | MX2016009888A (es) |
| MY (1) | MY199494A (es) |
| RU (1) | RU2733377C2 (es) |
| SG (2) | SG10202001028QA (es) |
| TW (1) | TWI722003B (es) |
| UY (1) | UY36801A (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10570194B2 (en) | 2015-08-06 | 2020-02-25 | Grifols Worldwide Operations Limited | Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM) |
| US9913903B2 (en) | 2015-08-06 | 2018-03-13 | Grifols Worldwide Operations Limited | Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM |
| KR102875179B1 (ko) * | 2018-11-30 | 2025-10-23 | 체에스엘 베링 아게 | 폴리클로날 면역글로불린을 사용한 급성 악화를 예방하거나 치료하기 위한 방법 및 조성물 |
| CN114747535B (zh) * | 2022-03-29 | 2024-03-22 | 华南理工大学 | 一种急性脓毒症非人灵长类动物模型及其构建方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) * | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4652533A (en) * | 1983-04-28 | 1987-03-24 | Pandex Laboratories, Inc. | Method of solid phase immunoassay incorporating a luminescent label |
| GB8426464D0 (en) | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
| US4918163A (en) | 1985-09-27 | 1990-04-17 | Pfizer Inc. | Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria |
| IL90281A (en) | 1988-06-06 | 1994-10-07 | Miles Inc | Preparations containing MGI antibodies |
| DE3825429C2 (de) | 1988-07-27 | 1994-02-10 | Biotest Pharma Gmbh | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt |
| DE3927111C3 (de) | 1989-08-17 | 1994-09-01 | Biotest Pharma Gmbh | Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate |
| US7473423B2 (en) | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
| DE60034778T2 (de) * | 1999-03-23 | 2008-01-31 | Hibernation Therapeutics Ltd., Townsville | Stoppen, schützen und konservieren von organen |
| RU2191031C2 (ru) * | 2001-01-10 | 2002-10-20 | Московский НИИ педиатрии и детской хирургии | Способ лечения пневмоний у глубоконедоношенных детей, находящихся на искусственной вентиляции легких |
| EP1587539B1 (en) * | 2003-01-16 | 2010-08-04 | Pedersen Medical A/S | Antimicrobial composition for local use on mucosal membranes and skin |
| EP1779849A1 (en) * | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of septic shock |
| US7794721B2 (en) * | 2006-12-13 | 2010-09-14 | Simon Michael R | Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith |
| GB0717864D0 (en) * | 2007-09-13 | 2007-10-24 | Peptcell Ltd | Peptide sequences and compositions |
| CA2707309A1 (en) * | 2007-12-18 | 2009-06-25 | Acumen Pharmaceuticals, Inc. | Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production |
| WO2009140236A2 (en) | 2008-05-12 | 2009-11-19 | Strox Biopharmaceuticals, Llc | Staphylococcus aureus-specific antibody preparations |
| US9913903B2 (en) | 2015-08-06 | 2018-03-13 | Grifols Worldwide Operations Limited | Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM |
-
2016
- 2016-05-05 US US15/147,226 patent/US9913903B2/en active Active
- 2016-07-18 EP EP16179975.4A patent/EP3150629A3/en not_active Ceased
- 2016-07-18 EP EP22150664.5A patent/EP4036110A1/en not_active Withdrawn
- 2016-07-19 UY UY0001036801A patent/UY36801A/es not_active Application Discontinuation
- 2016-07-20 CA CA2936745A patent/CA2936745A1/en active Pending
- 2016-07-24 IL IL246918A patent/IL246918B/en active IP Right Grant
- 2016-07-25 MY MYPI2016702695A patent/MY199494A/en unknown
- 2016-07-26 JP JP2016146097A patent/JP6901245B2/ja active Active
- 2016-07-26 AU AU2016208291A patent/AU2016208291B2/en active Active
- 2016-07-27 SG SG10202001028QA patent/SG10202001028QA/en unknown
- 2016-07-27 SG SG10201606200RA patent/SG10201606200RA/en unknown
- 2016-07-27 TW TW105123745A patent/TWI722003B/zh active
- 2016-07-28 MX MX2016009888A patent/MX2016009888A/es unknown
- 2016-07-28 RU RU2016131197A patent/RU2733377C2/ru active
- 2016-07-29 CN CN201610616759.1A patent/CN106421780A/zh active Pending
- 2016-08-04 AR ARP160102382A patent/AR105596A1/es unknown
- 2016-08-05 CL CL2016001977A patent/CL2016001977A1/es unknown
- 2016-08-05 KR KR1020160100183A patent/KR102739710B1/ko active Active
-
2018
- 2018-01-30 US US15/883,486 patent/US20180153991A1/en not_active Abandoned
-
2019
- 2019-06-28 US US16/456,689 patent/US10660956B2/en active Active
-
2020
- 2020-04-15 US US16/849,083 patent/US20200237912A1/en not_active Abandoned
-
2022
- 2022-08-17 US US17/889,875 patent/US12280110B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gao et al. | Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA) | |
| AR105596A1 (es) | PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCIÓN DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICIÓN QUE COMPRENDE IgM, COMPOSICIÓN | |
| JOP20220039A1 (ar) | صيغ ثابتة لمضاد حيوي من ببتيد سكري | |
| MX2019004611A (es) | Metodos y composiciones para cambiar la composicion del microbioma de la piel usando mezclas complejas de cepas bacterianas. | |
| BR112017004889A2 (pt) | uso antibacteriano de salicilanilidas halogenadas | |
| MX394895B (es) | Composiciones útiles para el tratamiento de infecciones por staphylococcus aureus. | |
| EP4477272A3 (en) | Polymyxin derivatives as antimicrobial compounds | |
| BR112015029367A8 (pt) | combinação compreendendo oxazolidinonaquinolonas, seu uso, composição farmacêutica, e kit de partes | |
| Matias et al. | Enhancement of antibiotic activity by Cordia verbenacea DC | |
| EA201690859A1 (ru) | Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli | |
| MX385898B (es) | Moleculas de fusion derivadas de la toxina colix para suministro oral de una carga biologicamente activa. | |
| CR20170425A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| MX2019001633A (es) | Proteina derivada de la seda para el tratamiento de la inflamacion. | |
| BR112016006589A2 (pt) | composição, e composição de vacina | |
| BR112022014555A2 (pt) | Composições de escherichia coli e métodos das mesmas. | |
| BR112017011478A2 (pt) | composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante | |
| BR112019008864A2 (pt) | composição herbácea, extrato de uma composição herbácea e processo de preparação, liofilizado, suplemento alimentar, composição nutracêutica, farmacêutica, veterinária ou cosmética ou alimento funcional ou aditivo alimentar e processo de preparação | |
| CO2018013753A2 (es) | Formulaciones de óxido de polialquileno-asparaginasa y métodos de preparación y uso del mismo | |
| BR112015011697A2 (pt) | antibióticos macrocíclicos de amplo espectro | |
| BR112017001093A2 (pt) | formulação aquosa compreendendo paracetamol e ibuprofeno | |
| PH12019501064A1 (en) | Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | |
| BR112015027636A2 (pt) | Uso da composição farmacêutica | |
| MX387476B (es) | Antibióticos de amplio espectro macrocíclico. | |
| WO2014130655A8 (en) | Compositions and methods to inactivate and/or reduce production of microbial toxins | |
| MX2016010699A (es) | Composiciones y metodos para tratar neutropenia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |